Combination therapy with glutaminase inhibitors and immuno-oncology agents
US10940148B2 · kind B2 · utility
0Cited by
12References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 1, 2019 |
| Grant date | Mar 9, 2021 |
| Priority date | — |
| Expiry date | Feb 1, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.